Portal de Periódicos da CAPES

Treatment strategies and clinical outcomes in consecutive patients with locally advanced pancreatic cancer: A multicenter prospective cohort

2020; Elsevier BV; Volume: 47; Issue: 3 Linguagem: Inglês

10.1016/j.ejso.2020.11.137

1532-2157

Marieke S. Walma, L. Brada, Susana I. S. Patuleia, J. G. A. M. Blomjous, Thomas L. Bollen, K. Bosscha, Rutger C. G. Bruijnen, Olivier R. Busch, Geert‐Jan Creemers, Freek Daams, Ronald M. van Dam, Sebastiaan Festen, Derk Jan de Groot, Jan Willem de Groot, Nadia Haj Mohammad, John J. Hermans, Ignace H. J. T. de Hingh, Emile D. Kerver, Maarten S. van Leeuwen, Christiaan van der Leij, Mike S.L. Liem, Krijn P. van Lienden, Maartje Los, Vincent E. de Meijer, Martijn R. Meijerink, Leonie J. Mekenkamp, Joost Nederend, C. Yung Nio, Gijs A. Patijn, Marco B. Polée, Hans Pruijt, Nomdo S. Renken, Steffi Rombouts, Thijs J. Schouten, Martijn W.J. Stommel, Maaike E. Verweij, Judith de Vos‐Geelen, Jan J. J. de Vries, Annelie Vulink, Frank J. Wessels, Johanna W. Wilmink, Hjalmar C. van Santvoort, Marc G. Besselink, I. Quintus Molenaar,

Renal cell carcinoma treatment

IntroductionSince current studies on locally advanced pancreatic cancer (LAPC) mainly report from single, high-volume centers, it is unclear if outcomes can be translated to daily clinical practice. This study provides treatment strategies and clinical outcomes within a multicenter cohort of unselected patients with LAPC.Materials and methodsConsecutive patients with LAPC according to Dutch Pancreatic Cancer Group criteria, were prospectively included in 14 centers from April 2015 until December 2017. A centralized expert panel reviewed response according to RECIST v1.1 and potential surgical resectability. Primary outcome was median overall survival (mOS), stratified for primary treatment strategy.ResultsOverall, 422 patients were included, of whom 77% (n = 326) received chemotherapy. The majority started with FOLFIRINOX (77%, 252/326) with a median of six cycles (IQR 4–10). Gemcitabine monotherapy was given to 13% (41/326) of patients and nab-paclitaxel/gemcitabine to 10% (33/326), with a median of two (IQR 3–5) and three (IQR 3–5) cycles respectively. The mOS of the entire cohort was 10 months (95%CI 9–11). In patients treated with FOLFIRINOX, gemcitabine monotherapy, or nab-paclitaxel/gemcitabine, mOS was 14 (95%CI 13–15), 9 (95%CI 8–10), and 9 months (95%CI 8–10), respectively. A resection was performed in 13% (32/252) of patients after FOLFIRINOX, resulting in a mOS of 23 months (95%CI 12–34).ConclusionThis multicenter unselected cohort of patients with LAPC resulted in a 14 month mOS and a 13% resection rate after FOLFIRINOX. These data put previous results in perspective, enable us to inform patients with more accurate survival numbers and will support decision-making in clinical practice.